Literature DB >> 23271281

Inhibitory effect of tanshinone II A on TGF II-β1-induced cardiac fibrosis.

Daixing Zhou1, Zhihui Li1, Liwei Zhang1, Chengye Zhan2.   

Abstract

This study examined the effect of tanshinone II A (TSN II A) on the cardiac fibrosis induced by transforming growth factor β1 (TGF-β1) and the possible mechanisms. Cardiac fibroblasts were isolated from cardiac tissues of neonatal Sprague-Dawley (SD) rats by the trypsin digestion and differential adhesion method. The cells were treated with 5 ng/mL TGF-β1 alone or pretreated with TSN II A at different concentrations (10(-5) mol/L, 10(-4) mol/L). Immunocytochemistry was used for cell identification, RT-PCR for detection of the mRNA expression of connective tissue growth factor (CTGF) and collagen type I (COL I), Western blotting for detection of the protein expression of Smad7 and Smad3, and immunohistochemistry and immunofluorescence staining for detection of the protein expression of phosphorylated Smad3 (p-Smad3), CTGF and COLI. The results showed that TGF-β1 induced the expression of CTGF, COL I, p-Smad3 and Smad7 in a time-dependent manner. The mRNA expression of CTGF and COL I was significantly increased 24 h after TGF-β1 stimulation (P<0.01 for all). The protein expression of p-Smad3 and Smad7 reached a peak 1 h after TGF-β1 stimulation, much higher than the baseline level (P<0.01 for all). Pretreatment with high concentration of TSN A resulted in a decrease in the expression of p-Smad3, CTGF and COL I (P<0.01). The protein expression of Smad7 was substantially upregulated after pretreatment with two concentrations of TSN II A as compared with that at 2 h post TGF-β1 stimulation (P<0.05 for low concentration of TSN I IA; P<0.01 for high concentration of TSN II A). It was concluded that TSN II A may exert an inhibitory effect on cardiac fibrosis by upregulating the expression of Smad7, suppressing the TGF-β1-induced phosphorylation of Smad3 and partially blocking the TGF-β1-Smads signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271281     DOI: 10.1007/s11596-012-1042-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

Review 1.  Cardiac fibroblasts: friend or foe?

Authors:  Troy A Baudino; Wayne Carver; Wayne Giles; Thomas K Borg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-14       Impact factor: 4.733

2.  Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart.

Authors:  Baiqiu Wang; Jianming Hao; Stephen C Jones; May-Sann Yee; Julie C Roth; Ian M C Dixon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-05       Impact factor: 4.733

Review 3.  The role of TGF-beta signaling in myocardial infarction and cardiac remodeling.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2006-10-07       Impact factor: 10.787

4.  Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of transforming growth factor beta-mediated cardiac fibrosis in experimental autoimmune myocarditis.

Authors:  Gabriela Kania; Przemyslaw Blyszczuk; Sokrates Stein; Alan Valaperti; Davide Germano; Stephan Dirnhofer; Lukas Hunziker; Christian M Matter; Urs Eriksson
Journal:  Circ Res       Date:  2009-07-23       Impact factor: 17.367

Review 5.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

6.  B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-ß1/smad7 pathway in vivo and in vitro.

Authors:  Jian-Gui He; Yi-Li Chen; Bai-Li Chen; Yi-Yi Huang; Feng-Juan Yao; Sheng-Long Chen; Yu-Gang Dong
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-08-28       Impact factor: 2.557

7.  Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction.

Authors:  Vanja Drobic; Ryan H Cunnington; Kristen M Bedosky; Joshua E Raizman; Vinit V Elimban; Sunil G Rattan; Ian M C Dixon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-05-04       Impact factor: 4.733

8.  c-Ski, Smurf2, and Arkadia as regulators of TGF-beta signaling: new targets for managing myofibroblast function and cardiac fibrosis.

Authors:  Ryan H Cunnington; Mansoreh Nazari; Ian M C Dixon
Journal:  Can J Physiol Pharmacol       Date:  2009-10       Impact factor: 2.273

Review 9.  Transforming growth factor-beta and fibrosis.

Authors:  Franck Verrecchia; Alain Mauviel
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

Review 10.  Smad regulation in TGF-beta signal transduction.

Authors:  A Moustakas; S Souchelnytskyi; C H Heldin
Journal:  J Cell Sci       Date:  2001-12       Impact factor: 5.285

  10 in total
  4 in total

1.  Spatiotemporal delivery of basic fibroblast growth factor to directly and simultaneously attenuate cardiac fibrosis and promote cardiac tissue vascularization following myocardial infarction.

Authors:  Zhaobo Fan; Zhaobin Xu; Hong Niu; Yang Sui; Haichang Li; Jianjie Ma; Jianjun Guan
Journal:  J Control Release       Date:  2019-09-12       Impact factor: 9.776

2.  Sodium Tanshinone IIA Sulfonate Ameliorates Bladder Fibrosis in a Rat Model of Partial Bladder Outlet Obstruction by Inhibiting the TGF-β/Smad Pathway Activation.

Authors:  Xiaoxiao Jiang; Yaping Chen; Haitao Zhu; Bo Wang; Ping Qu; Renfu Chen; Xiaoqing Sun
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

3.  Effects of tanshinone IIA on the transforming growth factor β1/Smad signaling pathway in rat cardiac fibroblasts.

Authors:  Cheng-Ye Zhan; Jin-Hui Tang; Dai-Xing Zhou; Zhi-Hui Li
Journal:  Indian J Pharmacol       Date:  2014 Nov-Dec       Impact factor: 1.200

Review 4.  Targeting Oxidative Stress and Endothelial Dysfunction Using Tanshinone IIA for the Treatment of Tissue Inflammation and Fibrosis.

Authors:  Tsuo-Cheng Lu; Yi-Hsiu Wu; Wei-Yu Chen; Yu-Chiang Hung
Journal:  Oxid Med Cell Longev       Date:  2022-04-07       Impact factor: 7.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.